François Baclesse
Welcome,         Profile    Billing    Logout  
 21 Trials 
50 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Joly, Florence
AxiPRO, NCT04764487: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

Recruiting
3
178
Europe
KidneyPRO, web-application, standard follow-up
Weprom, Pfizer, FLGXPL
Renal Cell Carcinoma Metastatic
06/23
06/25
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
SPICI, NCT05219318: Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

Recruiting
3
372
Europe
Combination PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause
University Hospital, Bordeaux
Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
01/25
01/25

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe, RoW
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
12/28
GETUG-AFU 42, NCT06496581: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Recruiting
3
500
Europe
177Lu-PMSA-617, Pluvicto®, Standard of Care, ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapy* or ADT with docetaxel* plus an ARSI (i.e abiraterone + prednisone, or darolutamide,) ± radiotherapy
UNICANCER, Novartis
Prostate Cancer Metastatic
02/33
08/39
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
CHIPPI, NCT03842982 / 2018-003680-62: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Recruiting
3
362
Europe
HIPEC, Hyperthermic intraperitoneal chemotherapy
Centre Oscar Lambret, Funding searching
Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma
08/27
08/28
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
ROCSAN, NCT03651206: Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Hourglass Jan 2019 - Jan 2019 : Initiation of P2/3 ROCSAN trial for recurrent ovarian carcinosarcoma
Active, not recruiting
2/3
196
Europe
Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
ARCAGY/ GINECO GROUP, Tesaro, Inc.
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
12/24
06/25
UTOLA, NCT03745950: UTerin OLAparib

Completed
2
147
Europe
Olaparib Oral Capsule, Placebo oral capsule
ARCAGY/ GINECO GROUP
Endometrial Carcinoma
05/23
09/24
MEGACEP, NCT02817958 / 2014-004678-41: Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Recruiting
2
37
Europe
Chemotherapy TIP, Chemotherapy TIP (paclitaxel, ifosfamide et cisplatine)
UNICANCER, National Cancer Institute, France
Penile Cancer, Squamous Carcinoma
09/26
09/28
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
GETUG-StORM-01, NCT04299646: A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Recruiting
2
77
Europe
Steretactic radiotherapy
Centre Francois Baclesse, National Cancer Institute, France, GETUG
Metastatic Renal Cell Carcinoma, Radiotherapy
09/25
01/26
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Recruiting
2
77
Europe
combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone
ARCAGY/ GINECO GROUP
LOCALLY ADVANCED CERVICAL CANCERS
12/30
12/30
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
EDEN, NCT05529251: De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

Recruiting
2
90
Europe
Radiotherapy boost, Carboplatin AUC7, 3 cycles of EP
Centre Leon Berard
Seminoma, Stage II
09/25
09/30
TROPHAMET, NCT04396223 / 2019-002814-38: Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

Recruiting
1/2
26
Europe
Avelumab Injection, Methotrexate 1 GM Injection
Hospices Civils de Lyon, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Gestational Trophoblastic Neoplasias (GTN)
04/25
10/28
GYNET, NCT04652076 / 2020-000172-38: GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting
1/2
240
Europe
NP137, Pembrolizumab, KEYTRUDA, Paclitaxel, Carboplatin
NETRIS Pharma, Merck Sharp & Dohme LLC, Centre Leon Berard
Endometrial Carcinoma, Cervix Carcinoma
10/25
07/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
VIVROVAIRE TR, NCT03418844: Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Active, not recruiting
N/A
268
Europe
Self-questionnaires of living conditions and quality of life, Cardiac, pulmonary, auditory and biological assessment
Centre Francois Baclesse, ARCAGY/ GINECO GROUP
Germ Cell Tumor, Sex Cord Stromal Tumor, Malignant Non-epithelial Ovarian Tumors
07/21
12/24
COG-IMMUNO, NCT03599830: Study of the Cognition of Patients Treated With Immunotherapy

Completed
N/A
90
Europe
Cognitive test passations
Centre Francois Baclesse
Patients With Cancer Who Start Immunotherapy, All Neoplasms
01/23
01/23
MOCA-2, NCT03299855: MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Completed
N/A
104
Europe
Passation of neuropsychological test
Centre Francois Baclesse, UCOG (Unite de coordination en Onco-Gériatrie)
Neoplasms
10/23
10/23
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Recruiting
N/A
327
Europe, RoW
ARCAGY/ GINECO GROUP
Ovarian Cancer
12/24
12/24
AFTERGYN2, NCT06553612: Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

Recruiting
N/A
268
Europe
Multidisciplinary assessment, Standard assesment, Observational cohort
Centre Francois Baclesse
Gynecologic Cancer, Remission
09/27
06/28
ALTERNATIVE, NCT06505018: Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Recruiting
N/A
472
Europe
Cureety techcare
UNICANCER, Cureety
Metastatic Triple-Negative Breast Carcinoma
05/26
09/27
QUALIOR, NCT03169075: Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program

Active, not recruiting
N/A
190
Europe
Supervised physical exercise programs, Adapted physical activity
UNICANCER, CAMI: Sport & Cancer
Home Based Standardised Adapted Physical Activity Programme, Patients Taking Oral Targeted Therapy for Metastatic Cancer
09/24
07/28
COG STIM 2, NCT06027632: Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

Recruiting
N/A
300
Europe
Cognitive exercises with supervision, Cognitive exercises without supervision
Centre Francois Baclesse, UNICANCER
Breast Cancer, Cognitive Dysfunction
06/28
03/29
STARTER, NCT05588700: Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients

Recruiting
N/A
236
Europe
Physical activity recommendations, Connected activity tracker, Physical Activity (PA) Intervention
Centre Leon Berard, National Cancer Institute, France
Metastatic Testicular Cancer
01/31
01/38
Mansi, Laura
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
RAINBO-RED, NCT06712472: Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer

Recruiting
3
554
Europe
Olaparib (300 mg BID)
Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca
Endometrial Cancer, P53abn
06/30
12/31
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
12/28
OVHIPEC-2, NCT03772028 / 2018-003346-17: Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Recruiting
3
538
Europe, US
cisplatin
The Netherlands Cancer Institute
Ovarian Cancer
04/25
04/26
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting
2
270
Europe
olaparib, durvalumab, tremelimumab
Centre Georges Francois Leclerc, AstraZeneca
Immunotherapy
08/27
08/27
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Recruiting
2
77
Europe
combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone
ARCAGY/ GINECO GROUP
LOCALLY ADVANCED CERVICAL CANCERS
12/30
12/30
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
EXOMA2, NCT04614480: Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Recruiting
2
2518
Europe
Exome analysis
Centre Georges Francois Leclerc
Cancer
09/25
09/29
RIBOLARIS, NCT05296746 / 2021-002322-24: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Recruiting
2
1100
Europe
Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant)
SOLTI Breast Cancer Research Group, Novartis, UNICANCER
Breast Cancer Stage II
10/29
12/31
ITHER, NCT02840058: Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Recruiting
N/A
120
Europe
Biological samples, Anti PD1/PDL1 treatment
Centre Hospitalier Universitaire de Besancon
Cancer
03/22
12/22
CACO-VAC, NCT04836793: COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2

Recruiting
N/A
300
Europe
Additional biological samples
Centre Hospitalier Universitaire de Besancon
Cancer, Elderly, Healthy Aging
03/22
03/23
IMMUNOPARP, NCT04675320: Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

Active, not recruiting
N/A
50
Europe
blood samples
Centre Georges Francois Leclerc
Ovarian Cancer
11/22
11/24
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Recruiting
N/A
327
Europe, RoW
ARCAGY/ GINECO GROUP
Ovarian Cancer
12/24
12/24
AFTERGYN2, NCT06553612: Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

Recruiting
N/A
268
Europe
Multidisciplinary assessment, Standard assesment, Observational cohort
Centre Francois Baclesse
Gynecologic Cancer, Remission
09/27
06/28
LARENA, NCT06599463: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

Completed
N/A
351
Europe
ARCAGY/ GINECO GROUP, Institut Curie
Metastatic Endometrial Cancer
02/25
02/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Joly, Florence
AxiPRO, NCT04764487: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

Recruiting
3
178
Europe
KidneyPRO, web-application, standard follow-up
Weprom, Pfizer, FLGXPL
Renal Cell Carcinoma Metastatic
06/23
06/25
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, PF-08046057, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen, a wholly owned subsidiary of Pfizer, Genmab
Cervical Cancer
07/23
05/26
SPICI, NCT05219318: Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

Recruiting
3
372
Europe
Combination PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause
University Hospital, Bordeaux
Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
01/25
01/25

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe, RoW
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
12/28
GETUG-AFU 42, NCT06496581: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Recruiting
3
500
Europe
177Lu-PMSA-617, Pluvicto®, Standard of Care, ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapy* or ADT with docetaxel* plus an ARSI (i.e abiraterone + prednisone, or darolutamide,) ± radiotherapy
UNICANCER, Novartis
Prostate Cancer Metastatic
02/33
08/39
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
CHIPPI, NCT03842982 / 2018-003680-62: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Recruiting
3
362
Europe
HIPEC, Hyperthermic intraperitoneal chemotherapy
Centre Oscar Lambret, Funding searching
Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma
08/27
08/28
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting
3
300
Europe
Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT
UNICANCER, Bayer
Prostate Cancer Metastatic
03/28
09/37
ROCSAN, NCT03651206: Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Hourglass Jan 2019 - Jan 2019 : Initiation of P2/3 ROCSAN trial for recurrent ovarian carcinosarcoma
Active, not recruiting
2/3
196
Europe
Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
ARCAGY/ GINECO GROUP, Tesaro, Inc.
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
12/24
06/25
UTOLA, NCT03745950: UTerin OLAparib

Completed
2
147
Europe
Olaparib Oral Capsule, Placebo oral capsule
ARCAGY/ GINECO GROUP
Endometrial Carcinoma
05/23
09/24
MEGACEP, NCT02817958 / 2014-004678-41: Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Recruiting
2
37
Europe
Chemotherapy TIP, Chemotherapy TIP (paclitaxel, ifosfamide et cisplatine)
UNICANCER, National Cancer Institute, France
Penile Cancer, Squamous Carcinoma
09/26
09/28
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
GETUG-StORM-01, NCT04299646: A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

Recruiting
2
77
Europe
Steretactic radiotherapy
Centre Francois Baclesse, National Cancer Institute, France, GETUG
Metastatic Renal Cell Carcinoma, Radiotherapy
09/25
01/26
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Recruiting
2
77
Europe
combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone
ARCAGY/ GINECO GROUP
LOCALLY ADVANCED CERVICAL CANCERS
12/30
12/30
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
EDEN, NCT05529251: De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

Recruiting
2
90
Europe
Radiotherapy boost, Carboplatin AUC7, 3 cycles of EP
Centre Leon Berard
Seminoma, Stage II
09/25
09/30
TROPHAMET, NCT04396223 / 2019-002814-38: Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

Recruiting
1/2
26
Europe
Avelumab Injection, Methotrexate 1 GM Injection
Hospices Civils de Lyon, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Gestational Trophoblastic Neoplasias (GTN)
04/25
10/28
GYNET, NCT04652076 / 2020-000172-38: GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting
1/2
240
Europe
NP137, Pembrolizumab, KEYTRUDA, Paclitaxel, Carboplatin
NETRIS Pharma, Merck Sharp & Dohme LLC, Centre Leon Berard
Endometrial Carcinoma, Cervix Carcinoma
10/25
07/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
VIVROVAIRE TR, NCT03418844: Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Active, not recruiting
N/A
268
Europe
Self-questionnaires of living conditions and quality of life, Cardiac, pulmonary, auditory and biological assessment
Centre Francois Baclesse, ARCAGY/ GINECO GROUP
Germ Cell Tumor, Sex Cord Stromal Tumor, Malignant Non-epithelial Ovarian Tumors
07/21
12/24
COG-IMMUNO, NCT03599830: Study of the Cognition of Patients Treated With Immunotherapy

Completed
N/A
90
Europe
Cognitive test passations
Centre Francois Baclesse
Patients With Cancer Who Start Immunotherapy, All Neoplasms
01/23
01/23
MOCA-2, NCT03299855: MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Completed
N/A
104
Europe
Passation of neuropsychological test
Centre Francois Baclesse, UCOG (Unite de coordination en Onco-Gériatrie)
Neoplasms
10/23
10/23
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Recruiting
N/A
327
Europe, RoW
ARCAGY/ GINECO GROUP
Ovarian Cancer
12/24
12/24
AFTERGYN2, NCT06553612: Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

Recruiting
N/A
268
Europe
Multidisciplinary assessment, Standard assesment, Observational cohort
Centre Francois Baclesse
Gynecologic Cancer, Remission
09/27
06/28
ALTERNATIVE, NCT06505018: Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Recruiting
N/A
472
Europe
Cureety techcare
UNICANCER, Cureety
Metastatic Triple-Negative Breast Carcinoma
05/26
09/27
QUALIOR, NCT03169075: Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program

Active, not recruiting
N/A
190
Europe
Supervised physical exercise programs, Adapted physical activity
UNICANCER, CAMI: Sport & Cancer
Home Based Standardised Adapted Physical Activity Programme, Patients Taking Oral Targeted Therapy for Metastatic Cancer
09/24
07/28
COG STIM 2, NCT06027632: Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

Recruiting
N/A
300
Europe
Cognitive exercises with supervision, Cognitive exercises without supervision
Centre Francois Baclesse, UNICANCER
Breast Cancer, Cognitive Dysfunction
06/28
03/29
STARTER, NCT05588700: Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients

Recruiting
N/A
236
Europe
Physical activity recommendations, Connected activity tracker, Physical Activity (PA) Intervention
Centre Leon Berard, National Cancer Institute, France
Metastatic Testicular Cancer
01/31
01/38
Mansi, Laura
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
RAINBO-RED, NCT06712472: Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer

Recruiting
3
554
Europe
Olaparib (300 mg BID)
Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca
Endometrial Cancer, P53abn
06/30
12/31
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
12/28
OVHIPEC-2, NCT03772028 / 2018-003346-17: Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Recruiting
3
538
Europe, US
cisplatin
The Netherlands Cancer Institute
Ovarian Cancer
04/25
04/26
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group, Korean Gynecologic Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting
2
270
Europe
olaparib, durvalumab, tremelimumab
Centre Georges Francois Leclerc, AstraZeneca
Immunotherapy
08/27
08/27
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Recruiting
2
77
Europe
combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone
ARCAGY/ GINECO GROUP
LOCALLY ADVANCED CERVICAL CANCERS
12/30
12/30
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
EXOMA2, NCT04614480: Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Recruiting
2
2518
Europe
Exome analysis
Centre Georges Francois Leclerc
Cancer
09/25
09/29
RIBOLARIS, NCT05296746 / 2021-002322-24: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Recruiting
2
1100
Europe
Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant)
SOLTI Breast Cancer Research Group, Novartis, UNICANCER
Breast Cancer Stage II
10/29
12/31
ITHER, NCT02840058: Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Recruiting
N/A
120
Europe
Biological samples, Anti PD1/PDL1 treatment
Centre Hospitalier Universitaire de Besancon
Cancer
03/22
12/22
CACO-VAC, NCT04836793: COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2

Recruiting
N/A
300
Europe
Additional biological samples
Centre Hospitalier Universitaire de Besancon
Cancer, Elderly, Healthy Aging
03/22
03/23
IMMUNOPARP, NCT04675320: Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

Active, not recruiting
N/A
50
Europe
blood samples
Centre Georges Francois Leclerc
Ovarian Cancer
11/22
11/24
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Recruiting
N/A
327
Europe, RoW
ARCAGY/ GINECO GROUP
Ovarian Cancer
12/24
12/24
AFTERGYN2, NCT06553612: Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

Recruiting
N/A
268
Europe
Multidisciplinary assessment, Standard assesment, Observational cohort
Centre Francois Baclesse
Gynecologic Cancer, Remission
09/27
06/28
LARENA, NCT06599463: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

Completed
N/A
351
Europe
ARCAGY/ GINECO GROUP, Institut Curie
Metastatic Endometrial Cancer
02/25
02/25

Download Options